Search This Blog

Thursday, April 24, 2025

Merck Slapped With Lawsuit Over Cancer Treatment

 Halozyme Therapeutics is suing Merck for patent infringement.

The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation that infringes on its patents. It has filed a lawsuit in a New Jersey district court.

Halozyme is taking issue with a form of Keytruda, still under review for regulatory approval, that can be delivered under the skin, or subcutaneously. Halozyme is arguing it developed the technology and that Merck is using it without having obtained a commercial license to do so.

Merck reported first-quarter earnings on Thursday and said sales of intravenous Keytruda increased 4% to $7.21 billion in the quarter.

Merck said the subcutaneous form of the drug has completed phase 3 clinical testing and is under review in the U.S. and Europe. It has the potential to increase access and save administration time, Merck said.

Merck didn't immediately respond to a request for comment.

https://www.morningstar.com/news/dow-jones/202504248413/merck-slapped-with-lawsuit-over-cancer-treatment

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.